Sponsor: Pennsylvania State University
Sponsor Study ID: BCC015
Study Title: Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
CTO #: 103253
NCT Number: NCT04301843
Phase: II
Protocol Type: Treatment
Age Group: Children
Disease Sites: Soft Tissue
Study Objectives: Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.